← Leaderboards
Warren A Andiman
Yale University
$685,888
Attributed
$685,888
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$685,888 · 4
By mechanism
M01$358,892 · 3
R01$326,996 · 1
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- Yung-Chi Cheng$16,454,542
- Evelyn Hsieh$3,189,238
- Jeannette R Ickovics$21,693,325
- Elijah Paintsil$5,045,527
- Richard S Schottenfeld$12,878,104
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman Immunodeficiency Virus 1Hiv InfectionsHuman Therapy EvaluationHuman SubjectPediatric AidsAids TherapyCombination ChemotherapyIndinavirLamivudineStavudineDrug Screening /EvaluationHuman Pregnant SubjectClinical TrialsChild (0-11)Virus LoadVirus ReplicationMicroorganism Disease ChemotherapyMolecular CloningNucleic Acid SequencePathologic ProcessPatient Oriented ResearchAntiaids AgentPhenotype
Grant awards (5)
ABNORMALITIES IN VERTICALLY HIV-INFECTED AND UNINFECTED CHILDREN AND YOUTH$6,472
M01 · FY2005 · RR
RANDOMIZED TRIAL OF PROTEASE INHIBITOR-INCLUDING VS. PROTEASE INHIBITOR-SPARING$9,276
M01 · FY2004 · RR
PHENOTYPE AND GENOTYPE OF HIV-1 STRAINS FROM CHILDREN$326,996
R01 · FY2000 · AI
INDINAVIR, STAVUDINE &LAMIVUDINE TREATMENT OF HIV-1 PEDIATRIC PATIENTS$317,355
M01 · FY2000 · RR
INDINAVIR, STAVUDINE &LAMIVUDINE TREATMENT OF HIV-1 PEDIATRIC PATIENTS$25,789
M01 · FY2000 · RR